Open Access
Research Article
Issue
Parasite
Volume 24, 2017
Article Number 16
Number of page(s) 6
DOI https://doi.org/10.1051/parasite/2017017
Published online 12 May 2017

© F. Beugnet et al., published by EDP Sciences, 2017

Licence Creative Commons
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

The cat flea, Ctenocephalides felis felis Bouché, 1835, is widespread all over the world [10, 14, 15, 23]. The infestation of cats and dogs, but also many other mammals including humans, is very common. Flea infestations often induce clinical signs in dogs such as pruritus, hair loss and flea allergy dermatitis [14, 19], and increase the risk of pathogen transmission including Bartonella spp. and Rickettsia felis [1]. The cat flea is also the intermediate host of a tapeworm, Dipylidium caninum (Linnaeus, 1758) [7, 8]. The tapeworm life cycle starts with the flea larvae ingesting the proglottids or egg packets containing the eggs of D. caninum in the environment; the eggs then hatch and the hexacanth embryos infect the flea larva. The hexacanth embryos develop in immature flea stages in 9 to 19 days to non-infective metacestodes that stay quiescent in the flea pupae [6, 20, 21]. Following the original description by Venard [24], Pugh identified seven morphological stages of the Dipylidium metacestode during its maturation and preferred to avoid using the term cysticercoid larvae [20, 21]. Once the adult flea emerges and infests a host, the metacestode quickly reactivates and matures into an infective metacestode stage in the flea within 1–3 days [20, 21, 24]. This development is temperature dependent (with an optimal temperature of 32 °C) and is related to the presence of the fleas on the host skin. Carnivores become infected through the ingestion of fleas containing infective cysticercoid larvae, and adult D. caninum are typically formed within 2–3 weeks and can stay alive in their hosts for up to 3 years. At that time, proglottids are eliminated by infected carnivores.

Dipylidium caninum is common worldwide, infecting both cats and dogs, and is zoonotic, even though human infection is very rare [7]. In a recent publication based on the collection of fleas on 435 cats and 178 dogs in Europe, 5.2% of 732 C. felis and 2.2% of 1969 C. felis were found to be infected by D. caninum, which indicates that this tapeworm is probably more common than veterinarians may think [5]. The main difficulty in diagnosis is the poor sensitivity of coproscopical examination of faeces because proglottids can leave their host actively not during defecation, and because they are mainly located on the surface of faeces that they can also leave [57].

The regular use of an effective anti-flea insecticide is important to protect pets against the various pathogenic effects related to flea infestation [10, 15]. Many insecticides and/or acaricides are available for use in cats and/or dogs in a variety of formulations [4]. It has previously been demonstrated with a fipronil-(S)-methoprene spot-on formulation (Frontline Combo®, Merial) that applying topical insecticide that kills fleas fast enough would prevent the transmission of D. caninum [2]. The preventive efficacy is based on the time needed for the metacestode to mature and become infective to dogs or cats after flea ingestion, which was estimated between 24 and 36 h mainly based on temperature increase on the host’s skin [20, 21]. This maturation of the metacestodes can be discerned by morphological changes, as originally described by Venard in 1938 [24]. In the present study, we assessed the protection against D. caninum infection conferred by the oral administration of NexGard Spectra® (Merial) to dogs. NexGard Spectra® is an oral chewable formulation containing afoxolaner, an insecticidal-acaricidal compound of the isoxazoline family, and milbemycin oxime, a nematodicidal compound [17]. It is intended to protect dogs against flea and tick infestation, and to deworm against gastro-intestinal nematodes as well as some other nematode infections (Dirofilaria immitis, Angiostrongylus vasorum) [9, 12, 16, 22]. Since milbemycin oxime is only nematodicidal, no efficacy is claimed against tapeworms. However, afoxolaner is used at 2.5 mg/kg minimum dose to provide rapid curative and sustained efficacy against fleas [3]. Based on several publications, the sustained speed of kill of afoxolaner against fleas ranges from 12 to 24 h for the duration of the month [3, 9]. Our hypothesis was that D. caninum-infected fleas should be killed before the maturation of the metacestodes, therefore the treatment would indirectly prevent dogs against this tapeworm infection.

Materials and methods

Production of fleas infected by Dipylidium metacestodes

To assess the prophylactic effect of anti-flea treatment, it was first necessary to produce Dipylidium-infected fleas. The methodology was described previously [2, 13]. In order to do this, donor dogs infected with D. caninum, as confirmed by proglottid observation in faeces, were also infested with C. felis fleas. Flea eggs and shed proglottids were collected in a paper-covered pan below the cages every 24 or 48 h. The contents were sieved to remove gross debris. The sieved material containing flea eggs, Dipylidium proglottids and egg packets, was placed in an incubator (at 25 °C) in Petri dishes. The flea eggs started hatching after approximately 2–3 days, and the flea larvae were maintained with the sieved material for another 2 days (i.e., up to about 6 days after sieving). The mixture was then transferred to a classic flea breeding unit, containing a mixture of sand and crushed dried cat food, to ensure that the flea larvae could feed and develop adequately to pupae and newly emerged fleas within 2 weeks. Dipylidium metacestode development occurred in parallel to flea development.

Design of the studies

This study was conducted in accordance with the VICH GL9 (June 2000) guidelines on Good Clinical Practice [11].

The experimental unit was designed in compliance with the South African National Standard “SANS 10386:2008 The care and use of animals for scientific purposes”. The protocols were submitted to the ClinVet Animal Ethics Committee (CAEC).

This was a parallel group, blind, randomised, negative control efficacy study (Table 1) [18]. It included two groups of 10 dogs each, selected from an enrolled group of 24 dogs. The four dogs with the lowest body weights were removed. The groups consisted of 10 dogs in the negative control group and 10 dogs in the NexGard Spectra® treated group.

Table 1.

Experimental design.

The study followed a randomised block design. The 20 selected dogs were ranked within sex in descending order of individual animal body weight and subsequently allocated to 10 blocks of two dogs each. Within blocks, dogs were randomly allocated to the two groups.

Assignment of codes (codes A and B) to the study groups and administration of the treatment was the responsibility of non-blinded personnel. All other people involved in the study were blinded to the group allocation. Permission to deblind the study after study termination was given by the sponsor representative via e-mail received on 11 November 2016.

The dogs included in the study were mixed breed dogs, originating from the facility, ≥ 6 months of age. These dogs had not been treated with a long-acting topical or systemic acaricide/insecticide during the 12 weeks preceding Day 0, and the females were not pregnant. They were acclimatised to the study site for 7 days before the start, and they were clinically healthy as determined by a veterinarian on Day −7. None of the dogs were removed from the study prior to study termination.

The dog cages were environmentally controlled for temperature (20 °C ± 4 °C). The floor size of each dog cage was 2.0 m × 3.0 m. On Day 35, after the final flea count and removal, all dogs were moved to an outside unit. The new dog cages consisted of a 1.70 m × 0.7 m enclosed sleeping area and an outside run of 1.70 m × 3.0 m. A roof covered the kennels and the dogs were not exposed to rain.

The dogs were kept individually and no physical contact between them was possible. However, dogs still had visual and auditory contact with conspecifics. They were fed once a day according to the food manufacturer’s recommendation.

The NexGard Spectra® treatment was administered once on Day 0 at the doses indicated in Table 2. The purpose was to administer a dose as close as possible to the minimum dose of afoxolaner (2.5 mg/kg) and milbemycin oxime (0.5 mg/kg), so that all dogs received a similar concentration of the active ingredients in mg/kg.

Table 2.

Administered tablet doses per individual dog in treated group.

Experimental infestation with D. caninum-infected fleas

All dogs were experimentally infested with 100 C. felis fleas that were infected with a dog strain of D. caninum, on Days 7, 14, 21 and 28. Three flea batches were used during the study. A sample of 30 fleas was examined before each weekly flea challenge. Each of the 30 fleas was dissected and then examined microscopically to determine the presence or absence of D. caninum metacestodes (Table 3). For the flea challenges, the fleas were deposited on the dorsal line of the dogs on each of the infestation days, and the dogs were allowed to groom freely. Fleas were not combed, counted nor removed until Day 35.

Table 3.

Flea batches and infection rates used per infection.

Clinical assessment

A veterinarian conducted a clinical examination on all dogs during acclimatisation for enrollment on Day −7 and then again on Days −2, 35 and 70. All the dogs were observed daily by technicians from Day −7 to Day 70 for their general health.

Based on the prepatent period of D. caninum [6, 7], the cage floors, sleeping areas and faeces were examined daily from Days 28 to 70 to determine the possible presence of cestode proglottids. The cage floors and sleeping areas were carefully scrutinised daily by a technician to find proglottids, whereas the faeces were collected and diluted in water for complete observation under binocular magnifier. As soon as a dog was diagnosed as infected, it was removed from the study and dewormed with an anthelmintic containing praziquantel (5 mg/kg) (Milbemax®, Elanco).

Based on the prepatent period of approximately 21 days, and the last flea infestation on Day 28, it was considered that taking a margin of 21 more days, after Day 70, there was no biological possibility that a negative dog would become positive.

Efficacy criteria

The assessment criterion was the presence or absence of D. caninum infection by daily macroscopical examination of both faeces and cage floors from Day 28 to Day 70.

Percentage efficacy at the end of the study was calculated using the following formula:where:

  • Tc = Total number of infected dogs in the negative control group;

  • Tt = Total number of infected dogs in the treatment group.

SAS Version 9.3 TS Level 1M2 was used for all the statistical analyses. The absence and presence of proglottids were compared between the groups using a χ2 test or a Fisher’s exact test when one or more of the cells had a frequency of five or less. The level of significance of the formal tests was set at 5%, all tests were two-sided.

The number of fleas collected from dogs in both groups at Day 35 was considered an informative criterion.

Results

On Day −2, the mean body weight of dogs was 16.76 kg (ranging from 12.74 kg up to 22.00 kg) for the negative control group, and 16.22 kg (ranging from 12.40 kg up to 19.26 kg) for the NexGard Spectra® treated group (p = 0.6462), indicating homogeneity at the time of inclusion.

One dog in the negative control group had bloody loose faeces once on Day 29. As the faeces of the dog were normal afterwards and the dog showed no other clinical signs (fever, pain, etc.), no concomitant therapy was required.

On Day 35, one dog from the treated group had erythema on the abdomen and inguinal area. The signs were mild and resolved spontaneously without therapy.

Another dog in the treatment group showed signs of hair loss on the left and right flanks during the study on Day 43. The dog received concomitant topical essential oil therapy (Dermoscent®, LDCA) and the skin condition started to improve. The hair loss was considered not related to the treatment.

The individual dog cage floors and faeces were examined daily for proglottids from Days 28 to 70. Seven out of the 10 dogs in the negative control group were found to be positively infected with D. caninum: one dog on Day 35, one on Day 37, one on Day 38, one on Day 43, one on Day 51, one on Day 63 and one on Day 65.

None of the 10 dogs in the treated group were found to be infected with D. caninum (Table 4).

Table 4.

Number of dogs infected by Dipylidium caninum.

In this study, a single treatment with orally administered NexGard Spectra® was thus 100% effective in preventing infection with D. caninum tapeworms in 10 dogs, after four weekly infestations with 100 fleas from a population infected by D. caninum.

A statistically significant difference was observed between the negative control group and the treatment group (p < 0.0031).

An arithmetic mean of 47.7 fleas were recovered from the untreated control dogs, whereas no fleas were recovered from the treated group on Day 35 (Table 5), corresponding to 100% efficacy against fleas at Day 35.

Table 5.

Fleas recovered from the control and treated dogs on Day 35.

Supplementary files illustrating the study are available at http://www.parasite.org/10.1051/parasite/2017017/olm

Discussion

As previously published [2, 13], the experimental flea-infection model worked well, producing a population of Dipylidium metacestode-infected fleas, at a rate of 10–33%. The production of infected fleas enables the design of specific studies assessing treatment and prevention against fleas and tapeworms in cats or dogs. Under natural field conditions, the infection rate of fleas seems to be quite low, from 2% to 5% of Dipylidium-infected fleas, based on recent flea surveys in Europe [5]. It can therefore be considered that the flea challenges used in this study were higher than the natural risk [2, 13]. As already demonstrated for two topical products (Frontline Combo® and Certifect®, Merial) and one collar (Seresto®, Bayer), the oral administration of NexGard Spectra® to dogs was 100% effective in preventing infections with D. caninum, despite the fact that 100 fleas were applied to each dog four times, at weekly interval (Days, 7, 14, 21 and 28). In order to demonstrate that this efficacy would be obtained whatever the weight of the treated dogs, the minimum effective dose was used (i.e. as close as possible to 2.5 mg/kg afoxolaner and 0.5 mg/kg milbemycin) instead of the commercial weight range. Animals infested with fleas groom themselves and ingest fleas. Dogs appear to ingest fewer fleas than cats, which could explain why all cats were found infected by Dipylidium in a previous study [2], whereas only seven out of eight dogs were infected during a 2-month period of flea infesting challenges using 250 fleas per challenge. In the present study, 7 out of 10 control dogs were infected after the 4 flea challenges using 100 fleas each. In order to provide protection against D. caninum infection, the anti-flea treatment needs to kill fleas before the maturation of the metacestodes [2, 20, 21]. Based on available data, it seems that metacestodes need 24–36 h to become infective for the definitive host, which is temperature-related [20, 21]. We assumed that by killing fleas within 12–24 h during the whole month [3, 9], even if killed fleas were ingested, afoxolaner provided an indirect protective effect against D. caninum infection.

In this study, the efficacy criterion was based on the collection of Dipylidium proglottids, either on dog’s faeces or on cage floors. Based on previous studies, this was demonstrated to be sensitive enough to recover all infected animals [2, 3]. Microscopical coproscopy is known to have poor sensitivity and would bring no any additional benefit to the experimental design used here. Dipylidium infection can also be assessed by polymerase chain reaction (PCR); it is of interest for epidemiological surveys based on flea analyses [5]. The sensitivity of the PCR technique on faeces may be impaired by inhibiting factors and high bacterial contamination. As the preventive efficacy is based on individual analysis, pooled PCR analysis of faeces would be of no interest here.

In this controlled study, protection was complete for the whole month. In addition to providing monthly flea and tick control and a deworming effect against roundworms, hookworms, whipworms, heartworm larvae and lungworm [12, 16, 17, 22], the regular monthly use of NexGard Spectra® should indirectly help to prevent the infection of dogs by D. caninum.

Conflict of interest

The first and last authors are employees of Merial, which produces the veterinary drugs used in these studies.

NexGard Spectra® and Frontline Combo® are registered trademarks of Merial. All other marks are the property of their respective owners. This document is provided for scientific purposes only. Any reference to a brand or trademark herein is for information purposes only and is not intended for any commercial purposes or to dilute the rights of the respective owners of the brand(s) or trademark(s).

References

  1. Beugnet F.. 2013. Guide to vector borne diseases of pets. Éditions Merial, Lyon, 425 p. ISBN 978-2-915578-40-5. (In the text)
  2. Beugnet F, Delport P, Luus H, Crafford D, Fourie J. 2013. Preventive efficacy of Frontline Combo® and Certifect® against Dipylidium caninum infestation of cats and dogs using a natural flea (Ctenocephalides felis) infestation model. Parasite, 20, 7. [CrossRef] [EDP Sciences] [PubMed] (In the text)
  3. Beugnet F, deVos C, Liebenberg J, Halos L, Fourie J. 2014. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. Parasite, 21, 42. [CrossRef] [EDP Sciences] [PubMed] (In the text)
  4. Beugnet F, Franc M. 2012. Insecticide and acaricide molecules and/or combinations to prevent pet infestation by ectoparasites. Trends in Parasitology, 28(7), 267–279. [CrossRef] [PubMed] (In the text)
  5. Beugnet F, Labuschagne M, Fourie J, Guillot J, Farkas R, Cozma V, Halos L, Hellmann K, Knaus M, Rehbein S. 2014. Occurrence of Dipylidium caninum in fleas from client-owned cats and dogs in Europe using a new PCR detection assay. Veterinary Parasitology, 205, 300–306. [CrossRef] [PubMed] (In the text)
  6. Boreham RE, Boreham PFL. 1990. Dipylidium caninum: life cycle, epizootiology and control. Compendium on Continuing Education, 12, 667–675. (In the text)
  7. Bourdeau P, Beugnet F. 1993. Téniasis des carnivores domestiques. Recueil de Médecine Vétérinaire, 169, 353–368. (In the text)
  8. Chappell CL, Pen HM. 1990. Dipylidium infection, an underrecognized infection in infants and children. Pediatric Infectious Disease Journal, 9, 745–747. [CrossRef] (In the text)
  9. Chester TS, Young DR, Fourie JJ, Larsen DL, Hunter JS, Dumont P. 2014. Evaluation of the curative and preventive efficacy of a single oral administration of afoxolaner against cat flea Ctenocephalides felis infestations on dogs. Veterinary Parasitology, 201, 207–211. [CrossRef] [PubMed] (In the text)
  10. Coles TB, Dryden MW. 2014. Insecticide/acaricide resistance in fleas and ticks infesting dogs and cats. Parasites & Vectors, 7, 8. [CrossRef] [PubMed] (In the text)
  11. EMEA. 2000. VICH Topic GL9 (GCP). Guideline on Good Clinical Practices. The European Agency for the Evaluation of Medicinal Products (EMWA/CVMP/VICH/595/98-Final), http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2009/10/WC500004343.pdf. (In the text)
  12. Fankhauser R, Hamel D, Dorr P, Reinemeyer CR, Crafford D, Bowman DD, Ulrich M, Yoon S, Larsen DL. 2016. Efficacy of oral afoxolaner plus milbemycin oxime chewables against induced gastrointestinal nematode infections in dogs. Veterinary Parasitology, 225, 117–122. [CrossRef] [PubMed] (In the text)
  13. Fourie JJ, Crafford D, Horak IG, Stanneck D. 2012. Prophylactic treatment of flea-infested cats with an imidacloprid/flumethrin collar to forestall infection with Dipylidium caninum. Parasites and Vectors, 5, 151. [CrossRef] (In the text)
  14. Guaguère E, Beugnet F. 2008. Parasitic skin conditions, in A Practical Guide to Canine Dermatology. Editions Kalianxis, Paris, p. 179–228, chap 14, ISBN 2-915758-11-5. (In the text)
  15. Halos L, Beugnet F, Cardoso L, Farkas R, Franc M, Guillot J, Pfister K, Wall R. 2014. Flea control failure? Myths and realities. Trends in Parasitology, 30, 5. [CrossRef] (In the text)
  16. Lebon W, Tielemans E, Rehbein S, Dumont P, Yoon S, Beugnet F, Jeannin P, Larsen D, Halos L. 2016. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. Parasites & Vectors, 9, 485. [CrossRef] [PubMed] (In the text)
  17. Letendre L, Harriman J, Drag M, Mullins A, Malinski T, Rhebein S. 2016. The intravenous and oral pharmacokinetics of afoxolaner and milbemycin oxime when used as a combination chewable parasiticide for dogs. Journal of Veterinary Pharmacology and Therapeutics, 40, 35–43. [CrossRef] [PubMed] (In the text)
  18. Marchiondo AA, Holdsworth PA, Fourie LJ, Rugg D, Hellmann K, Snyder DE, Dryden MW. 2013. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) second edition: guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestations on dogs and cats. Veterinary Parasitology, 194, 84–97. [CrossRef] [PubMed] (In the text)
  19. Prélaud P. 2008. Flea allergy dermatitis, in A Practical Guide to Canine Dermatology. Editions Kalianxis, Paris, p. 255–264, chap 16, ISBN 2-915758-11-5.. (In the text)
  20. Pugh RE, Moorhouse DE. 1985. Factors affecting the development of Dipylidium caninum in Ctenocephalides felis felis (Bouché, 1835). Zeitschrift für Parasitenkunde, 71, 765–775. [CrossRef] (In the text)
  21. Pugh RE. 1987. Effects on the development of Dipylidium caninum and on the host reaction to this parasite in the adult flea (Ctenocephalides felis felis). Parasitology Research, 73, 171–177. [CrossRef] [PubMed] (In the text)
  22. Rehbein S, Knaus M, Mallouk Y, Breiltgens T, Brianti E, Capári B, Dantas-Torres F, Gau M, Joachim A, Kaulfuß K, Kirkova Z, Lechner J, Mihalca A, Mirabito R, Petkevičius S, Rapti D, Shukullari E, Sedeilhan M, Dollhofer D, Kley K, Lebon W, Visser M, Jeannin P. 2017. Efficacy against nematode infections and safety of afoxolaner plus milbemycin oxime chewable tablets in domestic dogs under field conditions in Europe. Parasitology Research, 116, 259–269. [CrossRef] [PubMed] (In the text)
  23. Rust MK, Dryden MW. 1997. The biology, ecology, and management of the cat flea. Annual Review of Entomology, 42, 451–473. [CrossRef] [PubMed] (In the text)
  24. Venard CE. 1938. Morphology, bionomics and taxonomy of the cestode Dipylidium caninum. Annals of the New York Academy of Sciences, 37, 273–328. [CrossRef] (In the text)

Supplementary Material

(Access here)

All Tables

Table 1.

Experimental design.

Table 2.

Administered tablet doses per individual dog in treated group.

Table 3.

Flea batches and infection rates used per infection.

Table 4.

Number of dogs infected by Dipylidium caninum.

Table 5.

Fleas recovered from the control and treated dogs on Day 35.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.